FindTrial
Sign In

EVALUATION OF GLUCOSAMINES IN TEMPOROMANDIBULAR DISORDERS

GLUCOSAMINE AS AN ADJUVANT IN MANAGMENT OF TEMPOROMANDIBULAR DISORDERS :A RANDOMIZED CLINICAL TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045350
Enrollment
40
Registered
2022-09-08
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K088- Other specified disorders of teethand supporting structures Health Condition 2: M258- Other specified joint disorders

Interventions

Intervention1: aceclofenac 100 mg: oraly (TWICE DAILY) b.i.d 1 week Control Intervention1: GLUCOSAMINE 1500 mg od: PER ORAL Control Intervention2: glucosamine 1500 mg once daily: oral Control Interven

Sponsors

PULLURU RAMYA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.PATIENT WITH PAIN INVOLVING TEMPORO MANDIBULAR JOINT DISORDERS

Exclusion criteria

Exclusion criteria: 1.PSYCHIATRIC DISORDERS 2.CARDIOVASCULAR DISEASE 3.ASTHMA OR SELFISH ALLERGY 4.GASTROINTESTINAL PROBLEMS 5.KIDNEY OR LIVER DYSFUNCTION 6.DIABETES MELLITUS 7.TAKING ASPIRIN OR WARFARIN 8.CONCOMITANT TREATMENT OF TEMPOROMANDIBULAR DISORDERS WITH OTHER AGENTS OR METHODS

Design outcomes

Primary

MeasureTime frame
PAIN RELIEF TO PATIENTTimepoint: 3 MONTHS—

Secondary

MeasureTime frame
PATIENT WILL HAVE NORMAL OR NEAR MOUTH OPENINGTimepoint: 3 MONTHS—

Countries

India

Contacts

Public ContactDr RAKESH KUMAR MANEE

NARAYANA DENTAL COLLEGE AND HOSPITAL ,CHINTAREDDYPALEM.NELLORE

rmannae@rediffmail.com9704014747

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026